Equities

Cocrystal Pharma Inc

Cocrystal Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.76
  • Today's Change0.06 / 3.53%
  • Shares traded18.28k
  • 1 Year change+1.73%
  • Beta1.4755
Data delayed at least 15 minutes, as of Nov 08 2024 20:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

  • Revenue in USD (TTM)0.00
  • Net income in USD-17.93m
  • Incorporated2014
  • Employees12.00
  • Location
    Cocrystal Pharma Inc19805 N Creek PkwyBOTHELL 98011-8251United StatesUSA
  • Phone+1 (786) 459-1831
  • Fax+1 (302) 636-5454
  • Websitehttps://www.cocrystalpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IN8BIO, Inc.0.00-31.96m16.08m31.00--1.17-----0.8357-0.83570.000.29330.00----0.00-122.41-74.18-146.35-84.42------------0.0945-------5.21---4.54--
Traws Pharma Inc226.00k-137.05m16.10m16.00------71.25-138.17-138.170.25576.030.0092--12.9114,125.00-557.63-63.43-896.39-85.72-----60,641.15-3,257.92----0.00--0.00-28.720.0844------
Tenax Therapeutics Inc0.00-12.57m16.16m5.00--1.05-----22.35-22.350.004.530.00----0.00-101.95-199.16-113.79-285.64-----------95.940.0305------30.21------
Minerva Neurosciences Inc0.00-3.31m16.39m9.00---------0.4357-0.43570.00-3.100.00----0.00-6.25-49.89-6.75-52.39-------442.65------------6.55------
Geovax Labs Inc300.68k-26.92m16.62m17.00------55.29-13.05-13.050.1389-0.55260.0237----17,687.06-212.40-108.34-362.39-147.24-----8,951.51-1,842.93---------100.00---85.20------
Microbot Medical Inc0.00-10.44m16.83m22.00--2.69-----0.81-0.810.000.37930.00----0.00-113.94-53.28-133.34-62.65------------0.00------18.44---31.76--
Synlogic Inc3.17m-56.16m16.92m6.00--1.06--5.34-7.24-7.240.35491.370.0628----528,333.30-111.31-40.57-131.17-43.82-----1,771.74-3,245.93----0.00--185.685.9913.40---48.05--
Kairos Pharma Ltd0.00-2.01m17.21m-----------0.1562-0.15620.00-0.20670.00-------199.80-----------------15.58---------72.57------
Lyra Therapeutics Inc1.82m-101.39m17.52m87.00--0.5655--9.62-1.61-1.610.02940.47330.0165----20,681.82-92.07-58.01-108.51-68.69-----5,570.88-6,235.31----0.00--14.314.60-13.39--95.14--
Kazia Therapeutics Ltd (ADR)14.84k-13.47m17.76m12.00--1.65--1,196.48-8.17-8.170.00813.480.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Cocrystal Pharma Inc0.00-17.93m17.91m12.00--1.03-----1.76-1.760.001.710.00----0.00-61.98-50.94-66.88-52.77-------1,501.78----0.00------53.69--33.34--
Finch Therapeutics Group Inc0.00-14.17m18.95m18.00--1.33-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Aprea Therapeutics Inc1.31m-13.51m19.28m7.00--0.8791--14.71-2.81-2.810.26464.280.0498----187,262.90-51.30-68.66-60.22-77.19-----1,030.42-42,112.84----0.00------87.32--90.61--
Calidi Biotherapeutics Inc0.00-24.92m19.62m41.00---------5.41-5.410.00-1.820.00----0.00-279.89-----------------27.58-----100.00---14.90------
Unity Biotechnology Inc0.00-19.05m19.71m19.00--1.39-----1.14-1.140.000.83940.00----0.00-32.73-47.21-38.49-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Data as of Nov 08 2024. Currency figures normalised to Cocrystal Pharma Inc's reporting currency: US Dollar USD

Institutional shareholders

6.73%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2024275.66k2.71%
Renaissance Technologies LLCas of 30 Jun 2024129.83k1.28%
BlackRock Fund Advisorsas of 30 Jun 202473.75k0.73%
Geode Capital Management LLCas of 30 Jun 202464.83k0.64%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 202459.30k0.58%
G1 Execution Services LLCas of 30 Jun 202425.05k0.25%
SSgA Funds Management, Inc.as of 30 Jun 202420.54k0.20%
Dimensional Fund Advisors LPas of 30 Sep 202414.09k0.14%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202412.17k0.12%
Bank of America, NA (Private Banking)as of 30 Jun 20249.02k0.09%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.